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Abstract 
The effect of moxibustion on the in vitro and in vivo skin permeation of 
salicylate was evaluated in rats.  First, the effect of moxibustion pretreatment on the 
elimination pharmacokinetics of salicylate after i.v. injection in rats was determined: 
no clear difference was observed in the plasma profiles of salicylate (SA) with or 
without moxibustion pretreatment. However, much higher skin and muscle 
concentrations of salicylate were observed after its i.v. injection.  Next, an in vitro 
skin permeation study of SA was performed after moxibustion pretreatment. 
Moxibustion pretreatment increased the skin permeation of SA, and the extent of the 
increase in SA skin permeation was related to the strength of moxibustion ignition.  
More intense treatments produced higher skin permeation.  A similar enhancement 
effect on the skin permeation of SA was observed in in vivo studies.  Interestingly, 
the skin/plasma and muscle/plasma ratios of SA were markedly increased by 
moxibustion pretreatment.  These results were due to the induction of enhanced skin 
permeation and lower clearance into the cutaneous vessels by moxibustion ignition.  
Combination treatment involving moxibustion and the topical application of drugs 
such as NSAID may be useful for increasing local pharmaceutical effects by 
enhancing the drug concentration in the skin and muscle underneath the topical 
application site. 
 
Keywords: moxibustion, topical formulation, skin permeation enhancement, skin 
concentration enhancement, salicylate  
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1. Introduction 
Moxibustion therapy affects the blood flow in cutaneous tissues (Tawa, 2005) 
and muscles (Takagi et al., 2007; Matsumoto et al., 2005) as well as the barrier 
function of the stratum corneum (Cao et al., 2007).  It may also have an effect on the 
local vasodilatory response by increasing the temperature of the skin (Steif et al., 
2007).  When the body is in a warm environment, the veins and capillaries are more 
dilated than when it is in a cold environment, and blood flow is higher in warm than 
in cold environments (Peiffer et al., 2009).  Drug permeability through the 
endothelial membranes of blood vessels and capillaries is also higher in warm than in 
cold environments (Schimmelb et al., 1964; Nozaki et al., 1980).  In addition, the 
tight junctions in the endothelial membranes of blood vessels and capillaries are 
opened in inflamed conditions, and so drug molecules can easily permeate across the 
skin and reach the systemic blood circulation after their topical application to skin 
(Stewart et al., 1944; Arndt and Lipfert, 1993). The percutaneous absorption kinetics 
of topically applied drugs depend on the change in temperature induced by 
moxibustion treatment and the dose of drug applied. 
Numerous studies have evaluated the concurrent use of moxibustion with other 
physical technologies, especially acupuncture (Anastasi and McMahon, 2003; Sugai 
et al., 2004; Shin et al., 2006).  We have reported the change in the in vitro skin 
permeation efficacy of FITC-dextran with a mean molecular weight of 4 kDa (FD-4) 
induced by a single moxibustion technique (Cao et al., 2007).  We also found that the 
permeation rate and extent of FD-4 permeation through the skin were dependent upon 
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the application technique and type of moxibustion used in an in vitro skin permeation 
study.  However, the enhancement effect of drug permeation through skin cannot be 
verified with only in vitro data.  In vivo data is needed to prove the enhancement 
effect in addition to in vitro data.  We have already reported, however, that the drug 
permeation through excised human skin could be fairly predicted from that through 
hairless rat skin (Morimoto, Y. et al., 1992; Watanabe, T.et al., 2001).  Moxibustion 
treatment might cause skin irritation so that animal experiment instead of human test 
could be performed to assure the safety. 
In the present study, an in vivo hairless rat skin permeation study was performed 
in addition to an in vitro study.  Salicylic acid (SA) and its sodium salt (SA-Na) were 
used as model drugs, since the simultaneous use of an NSAID (non-steroidal 
anti-inflammatory drug) and moxibustion may be useful for treating muscle pain.  
Skin permeation as well as the skin and muscle concentrations of salicylate were 
determined to evaluate the effect of moxibustion.  
 
2. Methods 
2.1. Materials and animals 
SA-Na and Evan’s blue dye were purchased from Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan).  All other chemicals and solvents were of reagent 
grade and used without further purification. 
The SennenQ-off regular Q Ibuki was supplied by Senefa Co. (Nagahama, Shiga, 
Japan).  This moxibustion device has a moxa cylinder (5 mm diameter × 9 mm 
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length) and a pedestal.  Only the cylinder was used in the present experiment, and 
custom pedestals (diameter: 25 mm, thickness: 1-3 mm, hole diameter: 4 mm; Fig. 1) 
were made for the experiment. 
 
Fig. 1 
 
Healthy male hairless rats (WBN/ILA-Ht, body weight: 180-230g) were 
purchased from the Life Science Research Center of Josai University (Sakado, 
Saitama, Japan).  All animal feeding procedures and experiments were approved by 
the Institutional Animal Care and Use Committee of Josai University. 
 
2.2. Measurement of skin temperature 
One moxibustion cylinder was applied to the abdomen of each hairless rat (3 mm 
above the umbilicus on the midline) by fixing the animal on their back under 
anesthesia, which was induced by the i.p. injection of pentobarbital (40 mg/kg).  The 
distance between the cylinder tip and skin surface was set at 1.0, 2.0, or 3.0 mm.  
The moxibustion cylinder was ignited at 1.0 min and taken off at 6.0 min after 
application.  Thus, the firing period was 5.0 min.  The skin surface temperature and 
subcutaneous tissue temperature were determined according to the method described 
in our previous paper (Cao et al., 2007). 
 
2.3. In vitro skin permeation experiment 
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Moxibustion treatment (1 run for 5.0 min or 3 consecutive runs for 15 min) was 
performed on the abdominal skin of hairless rats (3 mm above the umbilicus along the 
midline), in the same manner as described above.  The distance between the cylinder 
tip and skin surface was set at 1.0, 2.0, or 3.0 mm.  The pretreatment area of the skin 
was carefully excised, and any underlying fat or muscle tissue was removed 30 min 
after the first ignition of the moxibustion cylinder.  The excised skin was 
immediately sandwiched between two half-diffusion cells with an effective diffusion 
area of 0.95 cm2 and a cell volume of 2.5 mL (Okumura et al., 1989).  The stratum 
corneum side of the skin was treated with 2.5 mL of 3% SA-Na in pH 7.4 phosphate 
buffered saline (PBS), while the dermis side was treated with the same volume of 
PBS.  Each compartment was magnetically stirred. Aliquots (500 µL) were 
withdrawn from the dermis side at predetermined time intervals, and fresh PBS was 
added after each sampling to keep the cell volume constant.  The temperature of the 
whole set was regulated at 32˚C by warm water circulation.  The SA concentration 
of the receiver solution was determined by HPLC. 
 
2.4. In vivo experiments 
2.4.1. Intravenous injection experiment 
Moxibustion treatment (3 times consecutively for 15 min) was performed on the 
abdominal skin of hairless rats (3 mm above the umbilicus along the midline), under 
anesthesia induced by the i.p. injection of urethane (1.0 g/kg).  The animals were 
kept on a waterbed kept at 37ºC during the in vivo experiment.  SA-Na (5 mg/kg) 
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was intravenously injected through the left jugular vein 30 min after the start of the 
first moxibustion session.  Blood sampling was performed periodically from the 
right jugular vein.  The obtained blood sample was centrifuged at 4 ºC to obtain 
plasma.  At the end of the experiment (8 h after the injection of SA-Na), the skin and 
muscle tissues (2.5 cm diameter under the moxibustion site) were excised, and the 
tissue samples were kept in a freezer until analysis.  The control i.v. injection of 
SA-Na was performed without moxibustion.  The SA concentrations in plasma and 
the tissues were determined by HPLC. 
 
2.4.2. Skin application experiment 
A glass diffusion cell with an effective diffusion area of 0.95 cm2 was applied to 
the skin surface where the moxibustion treatment was carried out.  SA-Na solution at 
a concentration of 20% (1.5 mL) was applied 30 min after the start of the first 
moxibustion session.  Plasma, skin, and muscle were obtained in the same manner as 
in the i.v. injection experiment. 
 
2.4.3. Appearance of i.v. injected Evan’s blue  
Moxibustion treatment (3 times consecutively for 15 min) was performed on the 
right abdominal skin of hairless rats, under urethane anesthesia.  Then, Evan’s blue 
(50 mg/kg) was intravenously injected, before pictures were taken of the 
moxibustion-application site as well as the control left abdomen site. 
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2.5. Salicylate determination methods  
The SA concentration was determined by a validated HPLC method with UV 
detection.  The receiver sample (100 µL) in the in vitro skin permeation experiments 
was added to acetonitrile (200 µL) containing an internal standard (propyl 
p-hydroxybenzoate) and centrifuged to obtain the supernatant. Acetonitrile (200 µL) 
containing the internal standard was added to the plasma sample (100 µL each), which 
was then centrifuged to obtain the supernatant.  The minced skin and muscle samples 
were added to acetonitrile (5.0 mL) containing the internal standard and physiological 
saline (4.0 mL) and homogenized using a Polytron (PT3000, Kinematic AG、
Switzerland) under iced water.  The homogenate was centrifuged at 4˚C.  Each 
supernatant (20 µL) was injected into an HPLC. 
The HPLC system (Shimadzu, Kyoto, Japan) comprised a model SLC-10A 
system controller, an SPD-10A UV detector, an LC-10A pump, and an SIL-10AXL 
autosampler.  The data were acquired and processed with a C-R6A chromatographic 
integrator (Shimadzu).  Chromatographic separation was achieved using 
LiChroCART® 250 × 4 mm (Merck KGaA, Darmstadt, Germany).  The mobile phase 
was a mixture of methanol and 0.1% phosphate water (55:45).  The flow rate of the 
mobile phase was 0.7 ml/min, and the UV wavelength was set at 225 nm. 
 
3. Results 
3.1. Effect of moxibustion on the skin temperature 
Figure 2a and b show the time courses of the temperature changes at the skin 
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surface and in the subcutaneous tissue, respectively, after one run of moxibustion.  In 
the experiment, a moxibustion cone was applied to the abdomen for 5.0 min.  The 
smoke had disappeared within 1.5 min, but the maximum temperature of the skin 
surface and subcutaneous tissue was observed at about 2.5 and 3 min after the start of 
moxibustion, respectively, when the moxibustion cone was still on the abdominal skin.  
The maximum temperatures at the skin surface and in the subcutaneous tissue 
produced by moxibustion with the 1, 2, and 3 mm-pedestals were 44.7, 46.5, and 
47.9ºC and 42.4, 43.7, and 45.6ºC, respectively.  The highest temperature in the 
subcutis was lower than that at the skin surface.  A short time lag was observed for 
the change in temperature from the skin surface to the subcutis.  These temperatures 
had returned to the control level (without or before moxibustion) within 10 to 15 min 
after the start of the moxibustion.  Since the skin permeation experiments were 
started 30 min after moxibustion ignition, the skin temperature during the permeation 
experiments was kept at 32 ºC using warm water circulation. 
 
Fig. 2 
 
3.2. Effect of moxibustion on the in vitro skin permeation of salicylate 
Figure 3 shows the effects of various moxibustion pretreatments on the time 
course of the cumulative amount of SA that permeated through excised hairless rat 
skin.  Table 1 summarizes the permeability coefficients of SA under each 
moxibustion treatment (the permeability coefficient can be obtained by dividing the 
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steady-state flux by the SA concentration in the donor solution).  The cumulative 
amount of SA over 8 h was 2.4-, 3.1-, 6.2-, and 21-fold higher than that observed in 
the control experiment (without moxibustion) during one run of moxibustion with 2 
mm-pedestal and three consecutive runs of moxibustion pretreatments with 3, 2, and 1 
mm-pedestal, respectively.  Increasing the number of moxibustion treatments and 
decreasing the pedestal thickness markedly increased the skin permeation of SA, 
which was also the case in in vitro studies using FITC-dextran (Cao et al., 2007). 
 
Fig. 3 and Table 1 
 
3.3. Effect of moxibustion on the elimination kinetics of salicylate 
Before evaluating the effects of moxibustion on the in vivo skin permeation of 
SA, SA-Na (5 mg/kg) was intravenously injected into rats, in order to evaluate the 
effect of moxibustion on the elimination kinetics of and the skin and muscle 
disposition to topically applied SA.  Figure 4 shows the time course of the plasma 
concentration of SA after i.v. injection, and Table 2 summarizes the pharmacokinetic 
parameters obtained with and without moxibustion.  Although the saturation 
kinetics for SA have been reported (Needs and Brooks, 1985), first-order elimination 
kinetics were observed in the present experiment.  No significant difference was 
observed in the elimination pharmacokinetics of SA with or without moxibustion, 
suggesting that moxibustion did not greatly affect the elimination kinetics of SA 
from the systemic circulation. 
 10 
 
Fig. 4 and Table 2 
 
Table 3 and Figure 5 show the amounts of SA in the skin and muscle under the 
moxibustion site and the skin/plasma and muscle/plasma ratios (s/p and m/p ratio) of 
SA 4 h after injection, respectively.  The plasma amount of SA was calculated from 
its plasma concentration and volume of distribution.  Since a similar plasma 
concentration range was observed, the same volume of distribution was used for all 
calculations, in spite of the dose dependent kinetics of SA (Needs and Brooks, 1985).  
The s/p and m/p ratios under moxibustion were about 4 and 2-fold higher, respectively, 
compared with those without moxibustion.  These results suggest that moxibustion 
treatment increased the skin and muscle concentrations under the site of moxibustion 
as well as the skin permeation of the drug.  In addition, the effect of moxibustion on 
the s/p ratio was more marked than that on the m/p ratio. 
 
Table 3 and Fig. 5 
 
3.4. Effect of moxibustion on the plasma level (in vivo skin permeation) of salicylate 
Figure 6 shows the time course of the plasma concentration of SA after its topical 
application.  Three-consecutive moxibustion pretreatments using a 1.0 mm pedestal 
were applied.  The plasma concentration increased almost linearly with the passage 
of time both with and without moxibustion pretreatment.  The plasma concentration 
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induced by moxibustion was about 5 times higher than that induced without 
moxibustion. However, the enhancement of the in vivo skin permeation of SA (about 
5 times) induced by moxibustion was lower than that the effect seen in the in vitro 
skin permeation experiment (about 21 times, see Fig. 3). 
 
Fig. 6 
 
Figure 7a and b show the effect of moxibustion on the s/p and m/p ratios of SA, 
respectively, 4 h after the start of its topical application.  Three-consecutive 
moxibustion pretreatments involving 1.0 mm pedestals were also performed in this 
study.  The s/p and m/p ratios produced by moxibustion were about 3 and 15 times 
higher than those produced without moxibustion, respectively. Since the plasma 
concentration itself was increased by moxibustion (see Fig. 6), the skin and muscle 
concentrations produced by moxibustion were calculated to be about 13 and 81 times 
higher than those produced without moxibustion (Table 4). 
 
Fig. 7 and Table 4 
 
3.5. Effect of moxibustion on the tissue distribution of i.v. injected Evan’s blue  
The effect of moxibustion treatment was evaluated on the leaching of Evan’s 
blue into the cutaneous and subcutaneous tissues from the systemic circulation in rats.  
Figure 8 shows the concentrated Evan’s blue dots that formed in the cutaneous and 
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subcutaneous tissues 25 min after moxibustion treatment and the i.v. injection of 
Evan’s blue.  The skin color became blue at the site of moxibustion, suggesting that 
Evan’s blue was easily delivered to the site of moxibustion after intravenous injection.  
The yellow color in Fig. 8 was due to the moxa resin. 
 
Fig. 8 
 
4. Discussion 
Although the moxibustion cylinder used in the present experiment was a 
commercially available model, the moxibustion treatment protocol used in the present 
study was a little more intense than the treatment protocol that is generally used in 
humans.  For example, the distance between the cylinder tip and skin surface and the 
thickness of the pedestal are 3 mm or more in the protocols used for general treatment.  
Therefore, the temperatures of the skin surface and the subcutis found in the present 
study must be higher than those produced during standard treatment.  High 
temperatures may cause severe inflammation of the skin and subcutaneous tissues 
(Fig. 2). 
SA was used as a model drug in the present study.  Thermodynamic energy 
affects skin permeation of drug.  The enhancement of drug permeation through skin 
after moxibustion treatment, however, was not obtained due to high skin temperature, 
because the skin temperature showed normal when drug was applied to the skin 
surface.  In addition,  the effect of moxibustion on the in vitro skin permeability of 
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SA was compared with that of FITC-dextran 4 kDa, which was reported in our 
previous study (Cao et al., 2007).  The enhancement ratio of FITC-dextran 
permeability; i.e., the permeability of FITC-dextran with/without moxibustion, was 
higher than that for SA.  This was due to the low permeability of the skin to larger 
compounds in the absence of moxibustion.   
Intense moxibustion may cause inflammation at the treatment site.  Igarashi et al. 
(2001) reported that intravenously injected lipid microspheres containing an 
anti-rheumatoid drug easily leaked from the epithelial membranes into inflammatory 
foci and that these phenomena were closely related to the high targeting ability of the 
anti-rheumatoid drug.  The inflammation probably expanded into the intercellular 
region or the tight junctions of cutaneous vessels so drugs in the systemic circulation 
may easily leach into inflammatory tissues (Tables 3 and 4).  This may be the reason 
for the higher effect of moxibustion on the in vitro skin permeation of SA compared 
with the in vivo skin permeation of SA (Figs. 3 and 6).  In addition, the in vivo skin 
permeation of SA may inhibit the recovery from inflammation at the site of 
moxibustion.   
 An i.v. SA injection experiment was performed to determine the volume of 
distribution of SA and evaluate the effect of moxibustion on the skin and muscle 
concentrations of SA.  The obtained volume of distribution was used to determine 
the s/p and m/p ratios of SA during moxibustion treatment.  These s/p and m/p ratios 
of SA clearly show the effects of moxibustion on the typical distribution of i.v. 
injected or topically applied SA (Figs. 5 and 7).  Some of the components of moxa, 
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such as 1,8-cineole, may be related to the penetration enhancing effect of moxibustion 
pretreatment. However, increases in the skin and muscle concentrations of SA at the 
site of moxibustion were observed, even after i.v. injection.  These phenomena are 
related to the effects of moxibustion on epithelial membranes in the viable 
epidermis/dermis and muscle.  The present results; i.e., the leakage of Evan’s blue 
from cutaneous and muscle blood capillaries, are similar to the phenomena described 
by Igarashi et al. (2001) (Fig 8).  In addition, increased drug leakage from cutaneous 
and muscle blood vessels must be one of the primary reasons for the increases in skin 
and muscle concentrations of SA induced by moxibustion. 
 
5. Conclusion 
The in vivo and in vitro skin permeation of SA was enhanced by moxibustion 
pretreatment. Moxibustion pretreatment also increased the skin and muscle 
concentrations of SA. Moxibustion can be utilized as a method for increasing the skin 
and muscle concentrations as well as the skin permeation of many kinds of topically 
applied drugs.  After that, we plan to evaluate and find out a safety condition after 
different for moxibustion treatments in human. 
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Table 1  Permeability coefficient of salicylate through excised hairless rat skin 
Each value represents the mean ± S.E., n = 5-7. 
 
Type of treatment Permeability coefficient 
(cm/s) 
Without moxibustion (2.33 ± 0.01) × 10-8 
1 run of moxibustion with a 2 mm pedestal (4.53 ± 1.47) × 10-8 
3 consecutive runs of moxibustion with a 1 mm pedestal (3.71 ± 0.01) × 10-7 
3 consecutive runs of moxibustion with a 2 mm pedestal (1.25 ± 0.01) × 10-7 
3 consecutive runs of moxibustion with a 3 mm pedestal (7.56 ± 0.01) × 10-8 
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Table 2  Elimination pharmacokinetic parameters of salicylate 
 
 
 
 
 
kel : first order elimination rate constant, Vd: volume of distribution 
Each value represents the mean ± S.E. (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment kel  (h-1) Vd  (ml) 
Without moxibustion (1.83 ± 0.18) × 10-3 31.5 ± 2.0 
3 consecutive runs of 
moxibustion using a 
1 mm pedestal 
(2.26 ± 0.17) × 10-3 29.7 ± 2.1 
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Table 3  Salicylate amounts in the skin and muscle 4 h after i.v. injection  
 
 
 
 
Each value represents the mean ± S.E. (n = 3). 
*p < 0.05 Mann-Whitney-U test, compared with the control 
 
 
Treatment Skin (nmol) Muscle (nmol) 
Without moxibustion 5.42 ± 0.84 8. 68 ± 2.08 
3 consecutive runs of moxibustion  
with a 1 mm pedestal 15.7 ± 5.5* 17.1 ± 1.7* 
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Table 4  Salicylate amounts in the skin and muscle 4 h after skin application 
 
 
 
 
Each value represents the mean ± S.E. (n = 3). 
*p < 0.05 Mann-Whitney-U test, compared with the control 
Treatment Skin (nmol) Muscle (nmol) 
Without moxibustion 1.61 ± 0.44 0.06 ± 0.01 
3 consecutive runs of moxibustion  
with a 1 mm pedestal 21.1 ± 1.8* 4.89 ± 0.59* 
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Figure Captions 
 
Fig. 1  Schematic view of the moxibustion cylinder and pedestal 
Fig. 2  Effect of moxibustion treatment on the temperature changes at the skin 
surface (a) and in the subcutis (b) (  : 1 mm thickness pedestal,  : 2 mm 
thickness pedestal,  : 3 mm thickness pedestal) 
Each line represents the mean value of at least 3 experiments. 
Fig. 3  Effect of the number of moxibustion cylinders (a) and the distance between 
the cylinder tip and skin surface (b) on the in vitro skin permeation of 
salicylate (●: control, ◊: 1 run of moxibustion with a 2 mm pedestal, ♦: 3 
consecutive runs of moxibustion with a 1 mm pedestal, ▲: 3 consecutive 
runs of moxibustion with a 2 mm pedestal, ■: 3 consecutive runs of 
moxibustion with a 3 mm pedestal) 
Each data point represents the mean ± S.E.(n=5-7). 
Fig. 4  Effect of moxibustion treatment on the in vivo plasma concentration of 
salicylate following i.v. injection (●: control, ■: 3 consecutive runs of 
moxibustion with a 1 mm pedestal) 
Each point represents the mean ± S.E. (n=3-4). 
Fig. 5  Effects of moxibustion treatment on the ratio of salicylate in the skin (a) and 
muscle (b) to the plasma concentration 4 h after i.v. injection (■: control, □: 3 
consecutive runs of moxibustion with a 1 mm pedestal) 
Each column represents the mean ± S.E. (n=3). 
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Fig. 6  Effect of moxibustion treatment on the in vivo plasma concentration of 
salicylate following topical application (●: control, ■: 3 consecutive runs of 
moxibustion with a 1 mm pedestal) 
Each point represents the mean ± S.E. (n=3). 
Fig. 7  Effects of moxibustion treatment on the ratio of salicylate in the skin (a) and 
muscle (b) to the plasma concentration 4 h after topical application (□: 
control, ■: 3 consecutive runs of moxibustion with a 1 mm pedestal) 
Each column represents the mean ± S.E. (n=3). 
Fig. 8  Effect of moxibustion treatment on the tissue distribution of Evan’s blue 25 
min after i.v. injection 
Photograph of the hairless rat abdomen after the intravenous injection of     
Evan’s blue 
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Fig. 4 
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